PanOptica (Mount Arlington, NJ) a development-stage biopharma company focused on in licensing IND-stage ophthalmology assets, closed a $30M Series A financing. Participants include SV Life Sciences and Third Rock Ventures.

Kala Pharmaceuticals (Waltham, MA) an early-stage stealth-mode biopharma closed a $3M Series B financing. Participants may include Lux Capital, Polaris Venture Partners and Third Rock Ventures.

Nine Point Medical (Cambridge, MA) a development-stage medical device and diagnostic company focused on optical technologies for real-time in vivo pathology decision making, closed a $33M Series A financing. Participants include Third Rock Ventures and Prospect Venture Partners.
_________________________________________________________________________
OnBioVC is exceedingly thankful for among many things the steadfast support for all of our readers and subscribers. [...]

CytomX Therapeutics (San Francisco, CA) a development-stage biopharmaceutical company focused on protease-activated antibody therapeutics, closed a $30M Series B financing. Participants include Third Rock Ventures and Roche Venture Fund.

Rhythm Pharmaceuticals (Boston, MA) a clinical-stage small peptide company focused on diabetes, obesity and GI disorders, closed a $19M Series A financing, bringing the total round to $40M. Participants include MPM Capital, New Enterprise Associates and Third Rock Ventures.

Constellation Pharmaceuticals (Cambridge, MA) a development-stage biopharma focused on epigenetic therapeutic development in the field of oncology, closed a $4.8M Series B financing bringing the total round to $22M. Participants include S.R. One, Altitude Life Science Ventures, Third Rock Ventures, The Column Group and Venrock.

Ablexis (San Francisco, CA) a development-stage biotechnology company focused on a transgenic mouse antibody drug discovery platform, closed a $12M Series A financing. Participants include Third Rock Ventures and Pfizer Venture Investments.

ZafGen (Cambridge, MA) a clinical-stage company focused on small molecule therapeutics for the treatment of obesity, closed a $8.1M Series B financing, bringing the total round to $28M. Participants include Atlas Venture, Third Rock Ventures and GreatPoint Ventures.

Genetix Pharmaceuticals (Cambridge, MA) a clinical-stage gene therapy company whose lentiviral technology is focused upon severe genetic disorders such as adrenoleukodystrophy and beta-thalassemia, closed a $35M Series B financijng. Participants include Third Rock Ventures, Genzyme Ventures, TVM Capital, Forbion and Easton Capital.

Eleven Biotherapeutics (Cambridge, MA) a preclinical-stage biopharmaceutical company focused on protein therapeutics for the treatment of inflammation and coagulation disorders, closed a $35M Series A financing. Participants include Flagship Ventures and Third Rock Ventures.
_________________________________________________________________________
NOTE: New OnBioVC Friday feature coming, well…this Friday!

Alnara Therapeutics (Cambridge, MA) a clinical-stage biopharmaceutical company focused on liprotamase, a pancreatic enzyme replacement therapy, for the treatment of pancreatic insufficiency associated with cystic fibrosis, chronic pancreatitis, pancreatic cancer, pancreatectomy and other pancreatic conditions, closed a $35M Series B financing. Participants include MPM Capital, Third Rock Ventures, Frazier Healthcare and Bessemer Venture Partners.

Afferent Pharmaceuticals (Palo Alto, CA) a clinical-stage biopharmaceutical company focused on pain associated with conditions such as osteoarthritis, back pain, visceral pain and neuropathy, closed a $23M Series A financing. Participants include Third Rock Ventures, Pappas Ventures, Domain Associates and New Leaf Venture Partners.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb